Picture of Sartorius Stedim Biotech SA logo

DIM — Sartorius Stedim Biotech SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Brief: Sartorius Stedim Biotech Q1 Underlying EBITDA At EUR 229 Mln

April 16 (Reuters) - Sartorius Stedim Biotech SA STDM.PA:

PUBLISHES UNAUDITED FIRST QUARTER RESULTS FOR 2025

Q1 SALES AT 745 MILLION EUROS, UP 10.4 PERCENT

FY 2025 GUIDANCE: SALES REVENUE INCREASE OF ABOUT 7%,UNDERLYING EBITDA MARGIN OF AROUND 30 TO 31 %

Q1 UNDERLYING EBITDA AT 229 MILLION EUROS, EBITDA MARGIN AT 30.8 PERCENT

Q1 NET PROFIT OF 85 MILLION EUROS

OUTLOOK 2025: RATIO OF CAPITAL EXPENDITURE TO SALES REVENUE EXPECTED TO BE AROUND 13 %

Source text: ID:nEQ41J5mya

Further company coverage: STDM.PA

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 587 785 110;))

Recent news on Sartorius Stedim Biotech SA

See all news